The new patent is estimated to provide protection until March 2027.
Marshall CEO and president Daniel Gold said the patent represents another important milestone in their efforts to develop lead drug candidates into valuable treatment options for patients with cancer.
"Furthermore, this demonstrates our commitment to further strengthening the intellectual property portfolio we acquired earlier this year, which will be essential for partnering any of our drug candidates," Gold added.